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Retinoblastoma protein and E2-promoter binding factor (E2F) family members are important regulators of G1-S phase
progression. Deregulated E2F also sensitizes cells to apoptosis, but this aspect of E2F function is poorly understood.
Studies of E2F-induced apoptosis have mostly been carried out in tissue culture cells, and the analysis of the factors
that are important for this process has been restricted to the testing of a few candidate genes. Using Drosophila as a
model system, we have generated tools that allow genetic modifiers of E2F-dependent apoptosis to be identified in
vivo and developed assays that allow effects on E2F-induced apoptosis to be studied in cultured cells. Genetic
interactions show that dE2F1-dependent apoptosis in vivo involves dArk/Apaf1 apoptosome-dependent activation of
both initiator and effector caspases and is sensitive to levels of Drosophila inhibitor of apoptosis-1 (dIAP1). Using these
approaches, we report the surprising finding that apoptosis inhibitor-5/antiapoptosis clone-11 (Api5/Aac11) is a critical
determinant of dE2F1-induced apoptosis in vivo and in vitro. This functional interaction occurs in multiple tissues, is
specific to E2F-induced apoptosis, and is conserved from flies to humans. Interestingly, Api5/Aac11 acts downstream of
E2F and suppresses E2F-dependent apoptosis without generally blocking E2F-dependent transcription. Api5/Aac11
expression is often upregulated in tumor cells, particularly in metastatic cells. We find that depletion of Api5 is tumor
cell lethal. The strong genetic interaction between E2F and Api5/Aac11 suggests that elevated levels of Api5 may be
selected during tumorigenesis to allow cells with deregulated E2F activity to survive under suboptimal conditions.
Therefore, inhibition of Api5 function might offer a possible mechanism for antitumor exploitation.
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Introduction
A proper balance between cell proliferation and apoptosis
is crucial for organism development and function. Perturba-
tions in this balance underlie a variety of pathological
conditions, including cancer (for review, see [1]). E2-pro-
moter binding factor (E2F) family proteins are important
regulators of cell cycle progression and a major target for
regulation by the retinoblastoma protein (pRB) tumor
suppressor protein family (for review, see [2,3]). The pRB
pathway is functionally inactivated in most tumor cells, and
the resulting change in E2F activity is thought to allow
unchecked cell proliferation.
In addition to their ability to drive cell proliferation, E2F
proteins sensitize cells to apoptosis (for review, see [4,5]). E2F-
induced apoptosis limits the consequences of E2F dereg-
ulation to such an extent that tumorigenesis selects not only
for lesions in the pRB pathway but also for mutations that
suppress the apoptotic potential of E2F (for review, see [6,7]).
Studies in mice show that apoptosis signiﬁcantly limits
tumorigenic growth following pRB inactivation, and the cell
types that are most prone to tumorigenesis following the
inactivation of pRB-family members are those that are
intrinsically resistant to apoptosis [8–10].
While the effects of E2F on the control of cell cycle
progression are well known, the connections between E2F
and the apoptotic machinery are less well deﬁned. E2F-
induced apoptosis is a property associated with some E2F
family members (notably mammalian E2F1 and Drosophila
dE2F1) but not with others [11,12]. After acute DNA damage
in mammalian cells, E2F1 is selectively modiﬁed and activates
transcription from a subset of E2F-regulated promoters,
resulting in activation of a large number of apoptotic
regulators (for review, see [13]). However, the relative
importance of these targets appears to be context dependent.
In various studies, E2F1-induced apoptosis has been reported
to be p53 dependent, p53 independent, Apaf1 dependent,
Apaf1 independent, and p73 dependent [14–22]. Other studies
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expression of either pRB [23] or TopBP1 [24], by the addition
of serum [25], or by the activation of Akt signaling [26]. The
large number of E2F-inducible genes, together with incon-
sistencies between studies carried out in different cell lines,
raises the issue of whether there is one general mechanism of
E2F-induced apoptosis or whether E2F induces apoptosis in
different ways in different cell types. Studies in Drosophila
show that the overall impact of E2F regulation on the DNA-
damage response in vivo varies greatly between cell types
[27].
To date, the study of E2F-induced apoptosis has been
carried out primarily in tissue culture cells, and the analysis
of the factors that are important for this process has been
restricted to the testing of a few candidate genes. Because of
this, it is highly likely that many of the genes that are most
important for E2F-induced apoptosis in vivo have yet to be
identiﬁed. To identify these genes, a genetic screening
approach is required. Previous efforts have concentrated on
E2F-stimulated proliferation [28] and, thus far, the genetic
tools needed to study E2F-induced apoptosis have not been
described.
To ﬁll this void, we have exploited the Gal4/UAS
misexpression system in Drosophila to generate transgenic
lines with dosage-sensitive phenotypes that are caused by
dE2F1-induced cell death. Here we describe these stocks and
their utility to identify mutations that modify the extent of
E2F-induced apoptosis. Moreover, we link this in vivo
approach with in vitro studies in Drosophila cultured cells
designed speciﬁcally to validate the genetic interactions on
apoptosis per se. Using these reagents we show that apoptotic
inhibitor-5/antiapoptosis clone-11 (Api5/Aac11), a highly
conserved family of antiapoptotic proteins that have not
previously been linked to E2F, function as strong and speciﬁc
suppressors of E2F-dependent apoptosis. Api5/Aac11 is rate-
limiting for E2F-induced phenotypes in Drosophila in multiple
cell types and developmental contexts, and the genetic
interaction between E2F and Api5/Aac11 is conserved
between Drosophila and human cells. These results illustrate
the value of genetic approaches for the study of E2F-
dependent apoptosis, showing that despite the extensive
molecular studies of the E2F transcriptional program, addi-
tional tiers of regulation exist that have a signiﬁcant impact
on E2F-induced processes in vivo.
Results
Generation of E2F-Dependent Phenotypes
We sought visible phenotypes that were caused by E2F-
induced apoptosis and were suitable for genetic screening.
We used the Gal4-UAS system to express the Drosophila E2f
gene (dE2f1) in a tissue-speciﬁc manner [29] and screened a
collection of 50 Gal4 drivers that provided a broad assort-
ment of developmentally regulated patterns. We compared
the effects of expressing dE2f1 with the effects of expressing
known regulators of cell cycle progression such as cyclin E
(CycE), dacapo (dap), and human p21, or apoptosis regulators
such as reaper (rpr) or baculovirus caspase inhibitor, p35
(Figure 1). Each of these transgenes caused lethality when
combined with speciﬁc subsets of drivers, and in some cases
gene expression resulted in visible phenotypes. Interestingly,
in this general survey we noted that the consequences of
expressing dE2f1 closely paralleled the effects of expressing
the Drosophila proapoptic gene, rpr, but showed far less
similarity with the effects of expressing the cell cycle
regulator CycE. Because we sought to study dE2F1-dependent
apoptosis, we selected the combinations of transgenes in
which dE2f1 expression gave a visible phenotype that was
phenocopied by the expression of rpr, but not by CycE, and we
used these to generate stable stocks bearing dE2F1-depend-
ent phenotypes.
We found several novel dE2F1-dependent phenotypes that
gave stable stocks and appeared to be amenable to genetic
screening (Figure 1). A dE2F1-dependent wing phenotype,
generated by the Drosophila Actin 88F (Act88F) promoter, was
particularly useful and was characterized in more detail
(Figure 2). Transheterozygous crosses of Act88F-Gal4 and UAS-
dE2f1 produced gnarled and ventrally curved wings that
frequently contained blisters (Figure 2A and 2B). This
phenotype was found to be 100% penetrant and was
phenocopied by expression of other proapoptotic genes
from the same driver, such as rpr (Figure 2C). The expression
of the cell cycle genes CycE (Figure 2D) or string/cdc25 (stg)
(unpublished data), in contrast, gave no signiﬁcant wing
curvature or gnarling.
The pattern of expression generated by the Act88F driver
was visualized using a UAS-enhanced green ﬂuorescent protein
(EGFP) transgene. Act88F is expressed during the develop-
ment of ﬂight and thoracic muscles [30]. Consistent with this,
the earliest EGFP expression was detected in indirect ﬂight
muscles of the pupae (unpublished data). In addition, we
observed signiﬁcant EGFP expression in cells of the newly
eclosed wing blade (Figure 2E–2H). Coexpression of dE2f1
resulted in signiﬁcantly fewer EGFP expressing cells in the
wing (Figure 2I–2J), a change that we quantiﬁed ﬂuorometri-
cally in single ﬂies (Figure 2K).
To conﬁrm that the reduction of EGFP-positive cells was
due to apoptosis, wings of newly eclosed adults were stained
with acridine orange (AO) to identify apoptotic cells. In wild-
type discs, very few cells labeled with AO shortly after
eclosion (Figure 2L and 2N). However, dE2f1 expression
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Synopsis
The retinoblastoma protein (pRB) was the first human tumor
suppressor to be described, and it works by limiting the activity of
the E2F transcription factor. The pRB pathway is inactivated in most
forms of cancer, and, accordingly, most tumor cells have deregu-
lated E2F. Uncontrolled E2F drives cell proliferation, but it also
sensitizes cells to die (apoptosis). E2F-induced apoptosis is not well
understood, but it affects the development of cancer and,
potentially, could be exploited for cancer treatment. To date,
however, there have been very few studies of E2F-induced
apoptosis in animal models. The authors describe a series of genetic
tools that allow systematic studies of E2F-induced apoptosis in
Drosophila. As validation, this approach identified some known
regulators of E2F-dependent apoptosis and also identified Api5, a
little-studied gene that had not previously been linked to E2F, as a
potent suppressor of E2F-induced cell death. The effects of Api5 on
E2F occur in several different tissues and are conserved from flies to
humans. This last point is significant since Api5 is upregulated in
cancer cells. The discovery of the E2F–Api5 interaction demonstrates
that important modulators of E2F-induced apoptosis are waiting to
be discovered and that they can be found using Drosophila.Figure 1. Summary of the Gal4-Driven Phenotypic Comparison Screen
(A) Gal4 driver lines were crossed to various UAS alleles at 25 8C in order to identify novel dominant phenotypes. Phenotype modification was compared
relative to control chromosome w
1118. Crosses lethal to progeny are indicated in black, while viable crosses are indicated in white. Viable ‘‘escaper’’ flies
from lethal crosses are indicated (E). Phenotypes generated in viable or escaper progeny are also indicated for each cross (P).
(B) Expression of rpr and dE2f1 resulted in significant lethality in the majority of Gal4 lines tested.
doi:10.1371/journal.pgen.0020196.g001
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Api5 Abrogates E2F-Dependent Apoptosiscaused a punctate pattern of AO staining within the blistered
portion of the distal wing blade (Figure 2M and 2O). By 30
min after eclosion, both wild-type and dE2f1-expressing wings
demonstrate signiﬁcant levels of AO staining (unpublished
data), consistent with previous reports of programmed cell
death in the wing [31]. The punctate pattern of AO staining
induced by dE2F1 was signiﬁcantly different, and easily
distinguishable, from the diffuse pattern of staining seen
during the later wave of programmed cell death that occurs
in the newly eclosed wing. These observations show that dE2f1
expression induces premature cellular death, and we infer
that these dE2F1-induced changes perturb the multicellular
architecture of the wing epithelia, causing defects that
become set in place during wing maturation.
As a further test of the processes involved in this dE2F1-
induced phenotype, we crossed Act88F-Gal4,UAS-dE2f1 re-
combinant stocks with various UAS and mutant alleles
(Figure 3) and examined their genetic interactions. As
expected, the wing phenotype was completely suppressed by
the coexpression of the Drosophila pRB ortholog, Rbf (Figure
3D), or by the coexpression of a dominant-negative form of
the dE2F1 heterodimerization partner, dDp (Figure 3E). These
proteins also blocked dE2F1-induced apoptosis, as measured
by the loss of EGFP-expressing cells (Figure 2K). Conversely,
expression of additional dE2f1 or the coexpression of func-
tional dDp strongly enhanced the wing defects (Figure 3I).
Taken together, with the suppression observed by dominant-
negative dDp, these data strongly suggest that the wing
phenotype is dependent on dE2F1-induced transcription.
Control UAS transgenes, such as UAS-EGFP and UAS-beta-
Figure 2. Generation and Characterization of Tissue-Specific dE2F1-Dependent Apoptotic Phenotypes in Drosophila
The Act88F-Gal4 driver was crossed to either a wild-type chromosome (w
1118;þ) (A), UAS-dE2f1 (B), UAS-rpr (C), or UAS-CycE (D). Expression of dE2f1 and
rpr, but not CycE, was sufficient to induce a ventrally curved, blistered, and gnarled wing phenotype. In order to visualize expression patterns, Act88F-
Gal4 was crossed to either a wild-type chromosome (Canton-S) (E and F) or UAS-EGFP transgene (G and H). Act88F drives expression in the newly eclosed
adult fly wing blade cells, and coexpression of dE2f1 removes many EGFP-positive cells (I and J). EGFP expression was quantitatively determined in
single transgenic flies by fluorescent spectrophotometry (K). Expression of dE2f1 significantly reduced the levels of EGFP and was rescued by
coexpression of Rbf, dDpDN,o rp35, but not p21. Newly eclosed wild-type wings (L and N) or dE2f1-expressing wings (M and O) were stained with AO to
visualize apoptotic cells. Cells expressing dE2f1 had strong, punctuate AO staining in the distal wing region where EGFP is mainly expressed early after
eclosion.
DIC, differential interference contract.
doi:10.1371/journal.pgen.0020196.g002
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Api5 Abrogates E2F-Dependent Apoptosisgalactosidase (lacZ), had no effect on the Act88F-Gal4,UAS-dE2f1
phenotype (Figure 3I).
We also tested for dominant interactions with various
alleles of known cell cycle regulators (Figures 2K and 3I).
Unlike Rbf, the expression of the human p21 cyclin-depend-
ent kinase inhibitor protein or the Drosophila p21 homolog
dap failed to suppress the Act88F-Gal4,UAS-dE2f1 phenotype.
Loss-of-function mutations in CycE, stg, Cdk1, Cdk2, or Cdk4
also failed to suppress the phenotype. Indeed, mutant alleles
of CycE and the overexpression of p21 caused a slight
enhancement of the wing defects. Taken together, with the
inability of CycE or stg to generate a similar phenotype, these
results suggest that the Act88F-driven dE2F1-dependent wing
phenotype is unlikely to be caused by cell cycle activation.
A clear pattern of strong genetic interactions emerged
when alleles of apoptotic regulators were tested. The dE2F1-
dependent phenotype was strongly suppressed by coexpres-
sion of the caspase inhibitors baculovirus p35 or Drosophila
thread/inhibitor of apoptosis protein-1 (dIAP1) (Figure 3F and 3G).
Accordingly, caspase expression alone phenocopied the
dE2F1 wing phenotype (Figure 3C). Caspase activity is
triggered by activation of apoptosome complexes which
regulate initiator caspase activation (for review, see [32]).
Accordingly, heterozygous loss-of-function alleles in the
Drosophila Apaf-1-related killer (dArk) were strong, dominant
suppressors of the Act88F-Gal4,UAS-dE2f1 phenotype (Figure
3H). In addition, loss-of-functional alleles of the endogenous
caspase inhibitor dIAP1 were strong enhancers of the
phenotype (Figure 3I). These interactions indicate that
apoptosome-caspase signaling is required for dE2F1-induced
apoptosis and that this in vivo E2F-dependent phenotype can
be dominantly modiﬁed by mutations in downstream
apoptotic signaling pathways. Interestingly, Act88F-Ga-
l4,UAS-dE2f1 was unaltered by the expression of various
dominant-negative alleles of Drosophila p53 (dp53) or by the
introduction of mutant alleles of dp53 (Figure 3I). Similar
results were found with other dE2F1-dependent phenotypes
(unpublished data). In mammalian cells, E2F-induced apop-
tosis can be either p53 dependent or p53 independent (for
review, see [33]); in Drosophila, dE2F1-induced apoptosis
appears to be primarily independent of dp53.
Taken together, these results show that expression of
dE2F1 under the control of the Act88F-Gal4 driver triggers
cell death. Act88F-Gal4,UAS-dE2f1 wings have a visible
phenotype that can be readily modiﬁed by transgenes that
affect E2F1 activity and by transgenes that induce or block
cell death. Moreover, this phenotype can be dominantly
enhanced or suppressed by heterozygous mutations in genes
Figure 3. Genetic Characterization of a Recombinant Act88F-Gal4,UAS-dE2f1 Transgenic Stock
Various alleles were analyzed for modification of the dE2f1-dependent phenotype in trans. The wild-type wing phenotype is depicted in Act88F-
Gal4,UAS-EGFP/þ (w
1118) recombinant stock as control (A). The Act88F-Gal4,UAS-dE2f1/þ (w
1118) recombinant stock phenotype (B) is strongly
phenocopied by caspase expression (C). Coexpression of Rbf (D) or dDpDN (E) completely suppressed the dE2f1 phenotype. The dE2f1-dependent
phenotype was also suppressed by various apoptotic regulators including coexpression of the caspase inhibitor baculovirus p35 (F) or dIAP1 (G) or a
heterozygous dominant allele of dArk (H), the Drosophila APAF1 homolog.
(I) Summary of the genetic interactions with Act88F-Gal4,UAS-dE2f1. The Act88F-Gal4,UAS-dE2f1 recombinant chromosome was crossed at 25 8Ct o
various transgenic and mutant alleles and phenotypes analyzed in transheterozygous progeny. Modification of the dE2F1 phenotype was compared
relative to control chromosome w
1118. See Materials and Methods for mutant alleles used in this study.
doi:10.1371/journal.pgen.0020196.g003
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sensitized background that can be used to screen for
mutations that have a signiﬁcant impact on dE2F1-induced
apoptosis.
Identification of Aac11 as a Modifier of dE2F1-Dependent
Phenotypes
We screened a collection of recessive-lethal P-element
transposon insertions for mutations that modiﬁed the Act88F-
Gal4,UAS-dE2f1 wing phenotype (see Materials and Methods).
Dominant modiﬁers were retested against four other dE2F1-
dependent phenotypes that were generated in the eye and in
bristle cells and were retested against other apoptotic
phenotypes to assess the speciﬁcity of the interactions (see
below). The primary question arising from this type of screen
was whether the modiﬁers isolated in this way do genuinely,
and speciﬁcally, affect E2F-dependent apoptosis. Therefore,
as described below, we have taken one such modiﬁer and have
characterized the interaction in detail.
The P-element insertion l(2)k06710 was a strong and
speciﬁc enhancer of dE2F1-dependent phenotypes in the
wing, eye, and bristles (Figure 4). The recessive-lethal
l(2)k06710 insertion failed to complement the genomic
deﬁciency Df(2L)H20, and a similar set of interactions were
observed using this deletion (unpublished data). Df(2L)H20
spans 36A8–9 to 36F1 of Chromosome 2L and uncovers the
l(2)k06710 insertion site within the ﬁrst exon of the Drosophila
Aac11 gene (Figure 5).
Aac11 is a member of the API5 gene family (Figure 5B).
Alignment of the human, mouse, frog, ﬂy, mosquito, and
plant API5 homolog products shows a high level of
conservation throughout the majority of the protein, as well
as a number of conserved protein domains (Figure 5C and 5D
and Discussion). Interestingly, the human Aac11/API5 gene,
also known as AAC-11/API5L1/FIF/MIG8 and hereafter re-
ferred to as API5 (NCBI Homologene), is located at
Chromosome 11p12–13 in a region frequently associated
with chromosomal aberrations including ampliﬁcation in
glioma and breast tumor cells [34,35]. Api5 is an antiapop-
totic protein ﬁrst described in a mammalian cDNA screen for
prosurvival genes; its expression promoted long-term cell
survival in the absence of serum [36]. Api5 expression has
been linked to tumorigenesis in a number of studies, although
its function is unknown [36–39].
The interaction between dE2f1 and Aac11 is highly speciﬁc;
l(2)k06710 did not modify rough eye phenotypes generated by
the expression of rpr, hid, dp53, CycE, or p21 (Table 1). In
addition, the effects of the Aac11 insertion on dE2F1 are most
likely downstream of RBF1 since the l(2)06710 insertion did
not modify phenotypes from Rbf transgenes (Table 1).
l(2)k06710 had no effect on an Act88F-Gal4,UAS-ced3 wing
phenotype that phenocopies Act88F-Gal4,UAS-dE2f1 (Table 1),
demonstrating that the mutation does not indirectly affect
the Act88F promoter or some aspect of Gal4 function. As
control, the Act88F-Gal4,UAS-ced3 phenotype was totally
suppressed by coexpression of p35 but unaffected by Rbf or
dominant-negative dDp (Figure S1).
Tissue-speciﬁc RNAi was used to conﬁrm that these
interactions were attributed to reduced levels of Aac11. An
inverted repeat speciﬁc to Aac11 (exons 1–3) was cloned
downstream of UAS binding sites [40], and transgenic UAS-
Aac11 RNAi (UAS-Aac11R) alleles were established. When UAS-
Aac11R alleles were combined with various wing Gal4 drivers
(engrailed, apterous, and Act88F), we observed dominant gnarled
and blistered wing phenotypes that resembled the effects of
dE2F1 expression (Figure 4L). These effects were dramatically
enhanced by the presence of a single l(2)k06710 allele (Figure
4M). When tested in the eye, expression of UAS-Aac11R gave
no phenotype alone but strongly enhanced the blackened and
rough eye phenotypes caused by GMR-regulated expression
of dE2f1 and dDp (Figure 4I–4K). Blacked areas of the eye have
been previously described (burned and scorched phenotypes)
and are characterized by pupal disc neurodegeneration [41].
Taken together, these results indicate that RNAi-mediated
depletion of Aac11 is sufﬁcient to enhance dE2F1-induced
phenotypes as well as to induce dominant phenotypes in the
ﬂy wing.
Aac11 Inhibits dE2F1-Dependent Apoptosis without
Generally Affecting dE2F1 Transcriptional Activity
In addition to apoptosis, wing gnarling and blistering can
be induced by a variety of different mechanisms that include
changes in cell fate, adhesion, and proliferation. To conﬁrm
that Aac11 affects dE2F1-dependent apoptosis, rather than
simply causing a synergistic disruption in tissue development,
we moved away from the context in which we had discovered
the connection between Aac11 and dE2F1 and reconstructed
this genetic interaction in cultured Drosophila cells (Figure 6).
A dE2F1-expression construct, or lacZ as control protein, was
introduced into SL2 cells together with a GFP-expression
construct that allowed us to visualize the transfected cells. As
expected from the proapoptotic activity of dE2F1, very few
GFP-positive cells were found in dE2F1-transfected cultures
compared to the lacZ control after 48 h (Figure 6A–6D). The
level of GFP expression was measured by ﬂuorimetry, and this
enabled the extent of dE2F1-induced cell killing to be
quantiﬁed (Figure 6E). The effects of dE2F1 were both time
and dosage dependent and quantitatively similar to the
changes seen when the proapoptotic Drosophila gene, hid, was
expressed as a positive control (unpublished data). As
expected, the effects of dE2F1 in this assay were inhibited
by the coexpression of RBF1 (Figure 6E).
Three lines of evidence conﬁrmed that the loss of GFP in
this assay was due to E2F1-induced apoptosis. First, a
signiﬁcant increase in the number of Hoechst 33258–positive
apoptotic chromatin-condensed nuclei was observed follow-
ing dE2F1 expression, compared to lacZ-transfected controls
(Figure 6F). Second, transfection of dE2F1 induced the
activation of both initiator and effector caspases (Figure 6G
and 6H). Third, the effects of dE2F1 were blocked by the
coexpression of either RBF1 or the baculovirus caspase
inhibitor p35 (Figure 6E).
Using this assay, we asked whether Aac11 activity was a
limiting factor for dE2F1-induced apoptosis by measuring the
level of dE2F1-induced death in cells depleted of Aac11 by
RNA interference (RNAi). Cells were treated with luciferase
double-stranded RNA (dsRNA) as nonspeciﬁc control, RBF1
dsRNA as positive control, or Aac11 dsRNA for 3 d and then
cotransfected with GFP and either lacZ or dE2F1 (along with
each dsRNA, respectively). As expected, depletion of RBF1
signiﬁcantly enhanced dE2F1-dependent death compared to
lacZ-transfected controls (Figure 6I). Depletion of Aac11 also
enhanced dE2F1-induced apoptosis to a level that was
comparable to that caused by the depletion of RBF1 (Figure
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Through genetic screening, the P-element insertion l(2)k06710 was identified as a strong enhancer of the Act88F-Gal4;UAS-dE2f1 apoptotic wing
phenotype (A). The arrow in (A) indicates enhanced ventral wing curvature and blistering in the l(2)k06710-enhanced dE2f1-dependent wing phenotype.
In secondary screening, l(2)k06710 was found to enhance multiple dE2f1-dependent phenotypes in different tissues including a nos-Gal4;UAS-dE2f1
notum bristle phenotype (B–D) and a GMR-Gal4,UAS-dE2f1,UAS-dDp rough eye phenotype (E–H). The l(2)k06710 insertion enhanced bristle degeneration
(compare arrows in [B] and [C]) and bristle stubble (arrowheads in [C]) induced by dE2f1 without inducing bristle phenotypes under heterozygous
conditions alone (D). Expression of a UAS-Aac11 RNAi allele also enhanced the dE2f1-induced rough eye resulting in a blackened phenotype (I–K).
Expression of the UAS-Aac11 RNAi allele under engrailed results in dominant posterior wing blistering which is enhanced by the l(2)k06710 P-insertion (L
and M).
doi:10.1371/journal.pgen.0020196.g004
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cycle phenotypes under these conditions (Figure 6K),
indicating that the changes were unlikely to result from a
nonspeciﬁc effect on cell number. These data indicate that
endogenous Aac11, like RBF1, suppresses the apoptotic
activity of dE2F1.
To ask whether Aac11 might repress the transcriptional
activity of dE2F1, we tested whether depletion of Aac11 by
RNAi altered dE2F19s ability to activate transcription.
Drosophila SL2 cells were treated with Aac11 dsRNA, or
nonspeciﬁc dsRNA to the white gene as control for 5 d, and
then transiently transfected with a wild-type or mutant
PCNA-lucif reporter construct. The reporter was titrated to
submaximal levels to ensure that either an increase or a
decrease in transcription could be measured. As expected,
dE2F1 transfection activated transcription from the wild-type
PCNA promoter but not a promoter with mutant E2F binding
sites (Figure 6J). The wild-type PCNA promoter, but not the
E2F-binding mutant, is activated by RBF1 RNAi [27].
However, no change in dE2F1-mediated activation was
observed in Aac11-depleted cells (Figure 6J). This indicates
that Aac11 depletion alters dE2F1-dependent apoptosis
without generally elevating dE2F1-dependent transcription;
hence, Aac11 most likely acts downstream of dE2F1-mediated
transcriptional activation. Although these data suggest that
Aac11 does not generally affect E2F-dependent transcrip-
Figure 5. Aac11 Is a Member of the Api5 Protein Family
(A) P-element l(2)k06710 insertion in the Drosophila Aac11 gene. The genomic locus of Aac11 on Chromosome 2L depicting P-insertion l(2)k06710 (þ187
nucleotides) in Aac11 exon1. This transposon failed to complement Df(2L)H20 covering region 36C9 but not the nearby deficiency Df(2L)VA18.
(B) Phylogenetic tree of Api5 family proteins. Nine Homologene-annotated homolog sequences (NCBI) were aligned using MegAlign PhyloTree
(DNAStar software, http://dnastar.com), using a Clustal method with PAM250 residue weight table. Additional species expressed-sequence tags are
present but not included here.
(C) Schematic of conserved Api5 protein domains.
(D) ClustalW multiple alignment of human, mouse, frog, fly, mosquito, and plant Api5 homologs with gray and black depicting amino acid similarity and
identity, respectively.
doi:10.1371/journal.pgen.0020196.g005
Table 1. Genetic Interaction of l(2)k06710 in Secondary Screen Phenotypes
Phenotype Genotype Phenotype Interaction
Other dE2F1-dependent phenotypes nos-Gal4,UAS-dE2f1 Deformed bristles Enhanced
GMR-Gal4,UAS-dE2f1 Rough eye Enhanced
GMR-Gal4,UAS-dE2f1,UAS-dDp Rough eye Enhanced
Other apoptotic phenotypes Act88F-Gal4,UAS-ced3 Gnarled wing No effect
GMR-rpr Rough eye No effect
GMR-hid Rough eye No effect
GMR-Gal4,UAS-dp53 Rough eye No effect
Other cell-cycle phenotypes en-Gal4,UAS-Rbf Notched wing No effect
GMR-p21 Rough eye No effect
GMR-Gal4,UAS-p21 Rough eye No effect
GMR-Gal4,UAS-cycE Rough eye No effect
doi:10.1371/journal.pgen.0020196.t001
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Api5 Abrogates E2F-Dependent ApoptosisFigure 6. RNAi of Aac11 Enhances dE2F1-Induced Apoptosis and Is Synthetic-Lethal with RBF1 RNAi
(A–D) Transfection of dE2F1 in Drosophila SL2 cells induces cell death as determined by co-transfected GFP loss.
(E) Quantitative measurements of GFP in dE2F1 transfections demonstrated significant GFP loss from dE2F1 that could be rescued by either RBF1 or p35
cotransfection (*p , 0.05 by t-test). Transfection of dE2F1 induced (F) apoptotic chromatin condensation in DAPI-stained nuclei in GFP-positive cells, (G)
caspase-3 activation, and (H) caspase-9 activation 48 h after transfection.
(I) RBF1 or Aac11 RNAi significantly enhanced dE2F1-dependent apoptosis (p , 0.01 by t-test). Cell survival was determined by GFP assay 48 h after
transfection.
(J) Aac11 RNAi does not affect dE2F1 transcriptional activation of the Drosophila PCNA promoter.
(K) Aac11 depletion does not alter cell cycle profiles in SL2 cells as determined by flow-cytometry analysis (div ¼ days in vitro after RNAi).
(L) Aac11 RNAi is synthetic lethal with RBF1 RNAi under conditions of low-serum stress. Cells were treated with dsRNA in serum-free media and split into
media with and without serum, and cell survival was determined 3 d after RNAi.
doi:10.1371/journal.pgen.0020196.g006
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Api5 Abrogates E2F-Dependent Apoptosistional activity, we cannot rule out potential effects of Aac11
on a subset of E2F promoters.
To test the idea that Aac11 affects dE2F1 in a manner that
is distinct from RBF1, we examined the effects of depleting
both Aac11 and RBF1. No signiﬁcant changes in cell survival
or proliferation were observed following the depletion of
either RBF1 or Aac11, or both, in the presence of serum
( F i g u r e6 L ) .H o w e v e r ,S L 2c e l l sa r em o r es e n s i t i v et o
apoptosis following serum deprivation. In these conditions,
cells that would normally survive if Aac11 and RBF1 were
depleted individually died when both proteins were depleted
(Figure 6L). This synthetic lethality conﬁrms that Aac11 and
RBF1 have independent functions and raises the possibility
that Aac11 may act generally to protect RBF1-deﬁcient cells
from E2F-induced apoptosis in contexts where survival
signals are limiting.
Api5 Suppresses E2F1-Induced Apoptosis in Human
Tumor Cells, and Api5 Depletion Is Tumor Cell Lethal
An underlying premise to this work is the idea that our
understanding of E2F-dependent apoptosis is incomplete.
Since much of the current information about E2F is derived
from studies in mammalian cells, it is important to know
whether novel functional interactions discovered in a genetic
screen in Drosophila are also relevant to studies of the
mammalian factor. To test the evolutionary conservation of
the genetic interaction between dE2F1 and Aac11, we
examined the effects of their homologs in human cells. Lines
of Saos-2 cells, a human osteosarcoma cell line that is both Rb
and p53 deﬁcient, were generated containing a tetracycline
(Tet)-responsive transgene controlling human E2F1 expres-
sion. A cDNA for the human API5 gene was cloned and used
to generate paired cell lines, with or without exogenous Api5.
Using these lines, we examined the effects of elevated E2F1
(Figure 7).
E2F1 expression in Saos-2 cells causes extensive apoptosis
(Figure 7A–7D) beginning at approximately 30 h post-
i n d u c t i o na n dp r e c e d e da n daccompanied by elevated
expression of various E2F target genes such as p14
ARF and
CycE (Figure 7H). Tet-induction in this system results in
signiﬁcant elevation of E2F1 over endogenous as observed by
Western analysis (Figure 7F–7H). Remarkably, the over-
expression of Api5 strongly inhibited E2F1-induced apoptosis
(Figure 7A–7D), giving signiﬁcantly enhanced cell survival
even when very high levels of E2F1 expression were sustained
for over 1 wk in culture (Figure 7E). Accordingly, the ability
of E2F1 to induce levels of apoptotic caspase-3 and PARP
cleavage was abrogated by exogenous Api5 (Figure 7F and
7G). However, the expression of Api5 did not prevent E2F1-
mediated induction of the E2F target genes p14
ARF and CycE
(Figure 7H). Thus, in human cells, as in Drosophila, Api5
suppresses E2F-induced apoptosis and most likely acts
downstream of E2F-induced transcription, although we
cannot rule out effects on other promoters at the moment.
To explore the speciﬁcity of Api5 action, control or Api5-
expressing Saos-2 cells were treated with or without
tetracycline, to induce E2F1, in the presence or absence of
the DNA-damaging agent camptothecin. Whereas Api5
protected cells from E2F1-induced death, it failed to protect
against apoptosis induced by camptothecin (Figure 7I).
Moreover, the ability of Api5 to protect against E2F1-induced
death was overridden by camptothecin treatment. Expression
of Api5 was also insufﬁcient to block death induced by
vinblastine, staurosporine, rotenone, or tumor necrosis
factor-alpha and had no effect on cell death induced by the
retroviral expression of p53 or p73 (unpublished data).
Hence, in human cells, as in Drosophila, Api5 proteins provide
a very speciﬁc protection against E2F-induced apoptosis, and
its protective activity distinguishes between these paradigms
of cell death.
Tumor studies have shown that Api5 is preferentially
expressed in squamous cell carcinoma versus adenocarcino-
ma in non–small cell lung cancer [38]. We hypothesized that
endogenous Api5 might be an important regulator of survival
in squamous cell carcinoma and tested this by reducing Api5
expression (Figure 8). shRNA constructs to Api5 were
designed, tested for their ability to deplete transfected
FLAG-tagged Api5 (Figure 8A), and then expressed from
lentiviral vectors (LLP) to target the endogenous Api5
protein (51-kDa doublet) in human squamous cell carcinoma
029 cells (JHU-029) (Figure 8B). JHU-029 cells are deﬁcient
for p16
INK4a [42] and endogenously express nuclear-localized
Api5 (Figure 8C and 8D). Compared to control WI38 human
diploid ﬁbroblasts, endogenous Api5 is highly expressed and
RNAi depletion of Api5 resulted in reduced survival with
higher sensitivity in the tumor cells (Figure 8E). In keeping
with the synthetic lethality between RBF1 and Aac11
depletion in SL2 cells, apoptosis was even more evident
when Api5-depleted cells were maintained in low-serum
(unpublished data). Taken together, the extensive pattern of
genetic interactions between E2F1 and Api5, and the
conservation of these interactions from ﬂies to humans,
underscores the signiﬁcance of Api5 for E2F1-dependent
apoptosis. Depletion of Api5 in E2F-deregulated tumor cells
results in reduced survival, and this raises the possibility that
Api5 may be a useful target for antineoplastic therapy.
Discussion
E2F-dependent apoptosis has been implicated in a wide
variety of pathophysiological settings, including DNA damage
signaling, neurodegeneration, and in the consequences of
pRB inactivation in cancer cells (for review, see [5,43,44]).
Very little is known about the regulation of E2F-dependent
apoptosis in vivo; most of our current knowledge comes from
studies of cultured cell lines. Because of this paucity of
information, we predict that many of the genes that have the
greatest impact on E2F-dependent apoptosis in vivo have yet
to be identiﬁed.
Here we describe a series of tools for the study of E2F-
induced apoptosis in Drosophila. Placing dE2F1 expression
under the control of the Act88F-Gal4 driver induces prema-
ture apoptosis in the developing wing, giving a gnarled and
blistered wing phenotype. These effects are dosage sensitive
and can be modiﬁed not only by changing the levels or
activity of dE2F1 but also by coexpressing regulators of cell
death and by heterozygous mutations in genes known to
function in cell death pathways. Indeed, similar phenotypes
can be generated by the misexpression of proapoptotic genes
from the same driver.
We note that Drosophila may be particularly advantageous
for the study of E2F-induced apoptosis. Since ﬂies have only
one activator E2F gene, and one DP gene, the way that
signaling pathways converge on E2F may be easier to dissect
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Api5 Abrogates E2F-Dependent ApoptosisFigure 7. Human Api5 Specifically Abrogates E2F1-Dependent Apoptosis without Generally Affecting E2F1-Dependent Transcription
(A–D) API5 stably expressing Saos-2 cells were generated with a Tet-inducible E2F1 transgene in the background. Following E2F1 induction by Tet
treatment, the parental cells undergo rapid widespread apoptosis; however, the Api5-expressing cells are highly resistant to E2F1-induced cell death.
(E) Api5-expressing cells survive and proliferate even following high and sustained levels of E2F1 expression. Cells were grown for 6 d after Tet re-dosing
every other day.
(F and G) Api5 reduces the levels of E2F1-mediated caspase-3 and PARP cleavage in both stable and Tet-inducible Api5 Saos-2 cells.
(H) Api5 expression does not inhibit the E2F1-mediated induction of target genes CycE and p14
ARF in Saos-2 cells.
(I) Api5 expression blocks death induced by E2F1 (þT) but not by treatment with the DNA-damaging agent camptothecin (CPT) as compared to DMSO
vehicle control (Veh). Saos-2 cell survival was assayed at 48 h by MTT.
doi:10.1371/journal.pgen.0020196.g007
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Api5 Abrogates E2F-Dependent Apoptosisin Drosophila than in mammalian cells (eight E2F and three DP
genes have been described to date). Several of the known
features of E2F1-induced apoptosis in mammalian cells are
conserved in ﬂies. For example, in the Drosophila wing, we ﬁnd
that dE2F1-dependent death is regulated by both dArk/Apaf1-
dependent apoptosome function and requires downstream
effector caspase activity as reported in mammalian settings in
vivo [20,45,46]. Moreover, we also found that this activity is
dominantly modiﬁed by dIAP1 in vivo. However, some aspects
of the mammalian interactions do not appear to be present.
For example, we failed to ﬁnd any evidence for genetic
interactions between dE2f1 and dp53. Several different path-
ways for E2F-induced apoptosis have been proposed for
mammalian cells, and the Drosophila model may most closely
resemble p53-independent forms of apoptosis induced by the
mammalian E2Fs. Understanding mechanisms of p53-inde-
pendent apoptosis by E2F1 is particularly important given the
high incidence of p53 mutations in human tumors.
While the Act88F-Gal4,UAS-dE2f1 wing phenotype provides
a sensitized background to identify modiﬁers of E2F-depend-
ent apoptosis, modiﬁcation of this phenotype does not
necessarily implicate a gene in dE2F-induced death. Muta-
tions that have synergistic or antagonistic effects on the
processes of wing development that are disrupted by dE2F1
will also change the severity of the phenotype. In this case, the
genetic interaction would inform us about the context in
which dE2F1 is being expressed but would not give us insight
into speciﬁc activities of E2F. A related, but different, issue is
the possibility that a mutation that affects cellular sensitivity
to apoptosis acts in general, rather than being speciﬁc to the
process of E2F-induced apoptosis. We therefore designed a
series of secondary assays to distinguish between classes of
modiﬁers.
One way to eliminate developmental context as the reason
for a genetic interaction is to look for interactions in different
tissues and different stages of development. We found that
UAS-dE2f1 expression from three additional drivers (sca-Gal4,
nos-Gal4, GMR-Gal4) gave visible phenotypes that could also be
suppressed by coexpression of RBF1, dominant-negative dDP,
or baculovirus p35 (GMR-Gal4, nos-Gal4; the sca-Gal4 pheno-
type is too severe). These phenotypes can also be dominantly
modiﬁed by heterozygous mutations, and we infer that
mutants that genetically interact with dE2F1 in multiple
different contexts are more likely to be informative. Of
course, a potential weakness of this rationale is that if E2F-
dependent apoptosis is controlled by tissue speciﬁc mecha-
nisms, then the genetic interactions might only occur in one
speciﬁc context. As an alternative strategy that completely
removes any potential contribution from developmental
context, we have also established assays for dE2F1-induced
apoptosis in tissue-culture cells. This assay system allows
candidate genes to be tested by both overexpression and loss-
of-function approaches (RNAi). In addition, the tissue culture
assays allow effects on the level and rate of dE2F1-dependent
apoptosis to be quantiﬁed precisely and open the way to more
mechanistic studies of genetic interactors.
Mutations that speciﬁcally affect dE2F1-induced apoptosis
could be distinguished from mutations that modify apoptosis
in general using Act88F-Gal4,UAS-ced3. Heterologous misex-
pression of this C. elegans caspase from the same Act88F-Gal4
driver gave a phenotype that was very similar to Act88F-
Gal4,UAS-dE2f1 but was insensitive to changes in E2F activity.
As an alternative, Act88F-Gal4,UAS-human caspase-1 could also
be used for this purpose (unpublished data). Other transgenes
such as GMR-hid and GMR-rpr provided additional tests for
speciﬁcity, using speciﬁc proapoptotic molecules and the eye
rather than the wing as the context to score interactions.
Using these tools, we made the unexpected ﬁnding that
Figure 8. Depletion of Human Api5 in p16
INK4a-Deficient Squamous Cell
Carcinoma Cells Results in Reduced Survival versus Normal Human
Fibroblasts
(A) RNAi-mediated depletion of transfected Api5. Various shRNA
constructs were tested for their ability to deplete FLAG-Api5 transfected
U2OS cells. The AB, CD, and EF (but not Scramble or AB-L) cotransfected
constructs strongly depleted Api5 expression after 3 d as determined by
anti-FLAG immunoblot.
(B) RNAi-mediated depletion of endogenous Api5 protein. JHU-029 cells
were infected with lentiviral encoding scramble or API5-AB shRNAs and
selected with puromycin for 3 d. Expression of endogenous Api5 was
determined by immunoblotting with affinity-purified anti-Api5 poly-
clonal antibody (G3162).
(C and D) Endogenous Api5 expression in JHU-029 cells is nuclear and
excluded from the nucleolus. JHU-029 cells were stained with the G3162
polyclonal antibody after 4% paraformaldehyde fixation.
(E) Api5 RNAi reduces survival of JHU-029 tumor cells as compared to
normal human fibroblasts. JHU-029 cells, as well as normal human WI38
diploid fibroblasts, were infected with lentiviral empty vector or vectors
encoding API5-AB shRNAs for 24 h and plated onto culture plates in 10%
fetal calf serum–containing media. Cell survival was determined by MTT
assay at the indicated days post–lentiviral infection. Api5 and control
actin expression was determined from equally loaded protein from day 3
lysates.
doi:10.1371/journal.pgen.0020196.g008
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Api5 Abrogates E2F-Dependent ApoptosisApi5 proteins are important and speciﬁc determinants of
E2F-induced death. As described here, the evidence for a
functional connection between E2F and Api5 is compelling:
(1) mutation of Aac11 enhances the phenotypes caused by
elevated levels of dE2F1 in the Drosophila wing, eye, and
bristles, (2) RNAi-mediated inhibition of Aac11 enhances
dE2F1-induced phenotypes in vivo and in tissue culture cells,
(3) RNAi depletion of Aac11 not only enhances dE2F1-
induced apoptosis but also is synthetic-lethal with depletion
of RBF1, (4) raising the level of Api5 strongly suppresses
E2F1-induced apoptosis, and (5) depletion of Api5 is
speciﬁcally lethal to tumor cells with deregulated E2F. These
genetic interactions are relatively speciﬁc in both Drosophila
and human cells; manipulating the levels of Api5/Aac11 did
not affect apoptosis induced by caspases, hid, rpr, p53, or
DNA-damaging agents.
API5 was initially isolated as a gene whose expression
promoted cell survival following serum deprivation [36].
Multiple studies have shown that the API5 mRNA transcript is
strongly expressed in transformed cell lines [36,37,47,48].
Consistent with this, we also found Api5 protein levels
signiﬁcantly elevated in tumor cell lines with known lesions in
the pRB pathway (JHU-029 cells versus WI38 ﬁbroblasts in
Figure 7E and unpublished data). Recently, Api5 expression
was reported to be repressed by myb [49] and activated by
mutant p53 [39]. In this latter study, API5 was one of a cluster
of genes that were upregulated by three different dominant
gain-of-function tumor-derived p53 missense mutants. In-
triguingly, in these cells, whereas wild-type p53 repressed
Api5, the p53 mutant alleles signiﬁcantly activated Api5
expression. Therefore, the API5 promoter may be speciﬁcally
deregulated in tumors cells harboring dominant p53 muta-
tions. In addition to its survival-promoting activity, Api5
overexpression has been reported to induce cervical tumor
cell invasiveness, and its expression has been found to be
upregulated in some metastatic lymph node tissues [37],
raising the possibility that it may be a metastatic oncogene.
Api5 expression has been linked to poor prognosis in non–
small cell lung cancer, and particularly in squamous cell
carcinoma [38].
The discovery that Api5 is a potent suppressor of E2F1-
induced apoptosis adds new signiﬁcance to these observa-
tions. The genetic interactions described here suggest that
Api5 may contribute to human malignancy by limiting the
extent of E2F1-dependent cell death, and we suggest that this
activity is particularly important when cells need to survive
under suboptimal conditions. The synthetic-lethality ob-
served with Aac11 and RBF1 depletion in low serum further
suggests that Api5 might also promote the survival of tumor
cells harboring pRb-inactivating mutations. Identiﬁcation of
new synthetic-lethal interactions is an important goal in
developing cancer-speciﬁc therapies that should, in theory,
reduce toxicity to normal cells [50]. Accordingly, RNAi-
mediated depletion of Api5 resulted in enhanced cell death
of p16-deﬁcient squamous cell carcinoma cells, as compared
to normal human ﬁbroblast controls. Although future studies
will be necessary to fully characterize the crosstalk between
E2F and Api5 signaling pathways, these ﬁndings indicate that
the levels of Api5 are likely to be very important for the
survival of human tumor cells with deregulated E2F. Hence,
Api5 may be an exploitable target for antineoplastic treat-
ment, particularly in tumors with pRb inactivation.
Future experiments are now necessary to identify the
molecular functions of Api5/Aac11. Orthologs of the API5
gene family are highly conserved in species as diverse as
plants and humans, but there are no obvious family members
in worms or yeast. Api5 proteins share a number of conserved
domains including a putative transactivation-domain ﬂanked
by two acidic domains, an LxxLL motif, a putative leucine
zipper domain, and a nuclear localization sequence. The
presence of these motifs suggests that Api5 family proteins
might be transcriptional regulators. Various deletion mutants
of Api5 possess strong transactivation activity when fused to
the DNA binding domain of Gal4 [47]. However, to date, no
target genes for Api5 have been described.
Perhaps one of the greatest advantages of the Drosophila
system is the opportunity for broad-based genetic screens,
and the tools described here allow novel interactors to be
quickly characterized and categorized. Further screening with
Act88F-Gal4,UAS-dE2f1 could reveal additional mutations
that, like Api5/Aac11, have a major impact on E2F-induced
apoptosis in vivo. One of the most interesting aspects of the
E2F–Api5 genetic interaction is the ﬁnding that it has been
conserved between ﬂies and humans during evolution. The
discovery of the connection between Api5 and E2F under-
scores the point that although molecular studies have
provided a great deal of information about the E2F-tran-
scriptional program, not all of the genes that have a major
impact on E2F-induced apoptosis in vivo have been identi-
ﬁed. These results illustrate the need for genetic screens for
mutations that have a signiﬁcant impact on E2F-induced
apoptosis and highlight the potential that components
isolated in this way may be highly relevant in other species.
Materials and Methods
Fly transgenes, stocks, and crosses. Unless otherwise noted, all ﬂy
crosses were conducted at 25 8C and phenotypes are depicted from
female progeny. The initial Gal4 screen was conducted by crossing
approximately 50 unique Gal4 lines to four different UAS-dE2f1 lines
(3
rd, 2BX, 5AII, and 3CII) at 18 8C, 25 8C, and, in some cases, 30 8C. The
recessive-lethal P-element transposon collection (approximately
2,200 lines) was a generous gift from Dr. Spyros Artavanis-Tsakonas
[51] and was F1 screened through the Act88F-Gal4,UAS-dE2f1 wing
phenotype and rescreened against the battery of secondary screens
described in the Results section. We isolated 30 strong suppressors
and two strong enhancers from the primary screen and the secondary
screens narrowed these to ten insertions, in four different loci, that
interacted with at least two additional dE2f1-dependent phenotypes
but failed to modify other apoptosis phenotypes. From these,
mutations in three loci acted as suppressors, and mutation in one
locuswasanenhancer(Aac11).Thefollowingstockswereusedforthese
studies (stock identiﬁcation numbers): w
1118, CycA
03946, CycE
AR95,
stg
01235, Cdk1
2,C d k 4
05428,C d k 4
06503,t h
l(3)j5C8,A a c 1 1
k06710 (10645),
Df(2L)H20 (3180), Df(2L)VA18 (6105), GUS-dp53
DN259H, GUS-dp53
DNCt,
UAS-EGFP (5431), UAS-lacZ (8529), UAS-dE2f1,UAS-dDp (4774), nanos-
Gal4 (4442), GMR-Gal4 (1104), and apterous-Gal4 (G2–1) (Bloomington
stock center); UAS-ced3 (6–6), UAS-caspase-1 (7–1) (Teiichi Tanimura);
UAS-dp53, dp53
4 , dp53
3þ (Michael Brodsky); dArk
CD4 (John Abrams);
engrailed-Gal4, sca-Gal4, UAS-p21, GMR-p21, UAS-dacapo (Iswar Har-
iharan); Act88F-Gal4 (2
nd) (Eric Fyrberg); Cdk1
E10, UAS-CycE (Christian
Lehner), UAS-rpr, GMR-rpr, UAS-hid, UAS-grim, GMR-hid, UAS-p35,
UAS-dIAP1 (Kristin White). The UAS-Rbf (4) stock was described
previously [52]. The following double-balanced or recombinant stocks
were created for these studies: (a) Act88F-Gal4,UAS-dE2f1 (B2)/CyO ftz
lacZ; (b) Act88F-Gal4,UAS-EGFP (A)/CyO ftz lacZ; (c) Act88F-Gal4,UAS-
EGFP,UAS-dE2f1 (3A)/CyO ftz lacZ; (d) Act88F-Gal4,UAS-ced3 (4)/CyO ftz
lacZ; (e) GMR-Gal4,UAS-dp53/CyO ftz lacZ; (f) GMR-Gal4/CyO; UAS-
dE2f1/TM6b; (g) GMR-Gal4,UAS-dE2f1,UAS-dDp/CyO ftz lacZ; (h) Sca-
Gal4/CyO, UAS-dE2f1/TM6b; (i) nos-Gal4,UAS-dE2f1/CyO ftz lacZ; (j) en-
Gal4,UAS-Rbf/CyO, ftz, lacZ; (k) GMR-Gal4,UAS-p21/CyO ftz lacZ; (l) GMR-
Gal4,UAS-CycE/CyO ftz lacZ; (m) en-Gal4,UAS-Aac11 RNAi (9A)/CyO ftz
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Api5 Abrogates E2F-Dependent ApoptosislacZ; and (n) en-Gal4,UAS-Aac11 RNAi (9A)/T(2:3) CyO TM6b. The UAS-
dDp dominant-negative allele (Chromosome 3) was created by subclon-
ing the dDp113–337 amino-acid fragment into the pUASt vector [29].
The UAS-Aac11 RNAi allele was created by subcloning an inverted
repeat of an XbaI fragment containing Aac11 59 UTR-exon3
sequences (primer set, 59- GCGCTCTAGAGCTGTCTCGA-
GATCTGGTCACTC and 59-GCGCTCTAGAGCGTTTCCCTGGCA-
CAGTTTC) into the pWIZ vector [40]. P-element transformation
was performed as described [53]. All transgenic ﬂy embryo injections
were performed by the CBRC Transgenic Fly Core.
AO staining and EGFP quantiﬁcation in single ﬂies. AO staining of
apoptotic cells in the wing was performed as described [54]. AO
positive cells were visualized with ﬂuorescent microscopy under FITC
ﬁlters (excitation k 490 nm, emission k 520 nm) and pseudocolor-
depicted. As positive control, we detected AO positive cells in the
posterior compartment of newly eclosed wings from en-Gal4/UAS-dp53
progeny (unpublished data). EGFP ﬂuorescence in individual newly
eclosed female ﬂies was quantiﬁed in single ﬂies as described [55].
EGFP ﬂuorescence was determined at excitation k 488 nm, emission k
511 nm (cutoff k 495 nm) with buffer background subtraction.
Fluorescent measurements were determined within a linear range
from a single UAS-EGFP transgene; two UAS-EGFP transgenes
produced 23 relative ﬂuorescent units (RFU) (unpublished data).
We did not detect squelching since expression of control protein
from a single UAS-lacZ transgene had no effect on EGFP ﬂuorescence
(unpublished data).
Cell culture and transient transfections. Drosophila Schneider line 2
(SL2 cells; ATCC, http://www.atcc.com) and mammalian cells were
grown as previously described [52,56]. Drosophila cell (CellFectin
reagent; Invitrogen, http://www.invitrogen.com) and human cell
(Fugene-6 reagent; Roche, http://www.roche.com) transfections were
performed according to the manufacturer’s recommended instruc-
tions. Luciferase reporter assays were performed as described [52].
The wild-type and E2F-binding mutant PCNA-luciferase reporter was
kindly provided [57].
Apoptosis and viability assays. Caspase-3 (DEVD-AFC peptide
substrate) and caspase-9 (LEHD-AFC peptide substrate) enzymatic
assays (R&D Systems, http://www.rndsystems.com) were performed
according to the manufacturer’s recommendations. Cleaved, acti-
vated ﬂuorescent substrate was measured in RFU and normalized to
total protein content (Bio-Rad, http://www.bio-rad.com). Cell viability
was determined by 0.4% trypan blue exclusion hemocytometry or
MTT assay [58]. Apoptotic chromatin condensation was assayed in
GFP-cotransfected live cells by incubating cultures with membrane-
permeant 50 lg/ml Hoechst 33258 dye (20 min; room temperature).
Nuclei with apoptotic condensed chromatin was visualized under
epiﬂuorescence and scored in ﬁve nonoverlapping ﬁelds per
condition expressed relative to total transfected. Transfected SL2
cell survival in six-well trays was determined by GFP cotransfection
viability assay [59] with 0.3 lg/well pAct-GFP
US9 (Act5c promoter)
expression construct. Cells were harvested by trituration, pelleted by
centrifugation, resuspended in PBS, and transferred to 96-well trays
for GFP ﬂuorescence quantiﬁcation. Plasmids used for these studies
were pIE4-dE2f1, pIE4-Rbf, pIE4-lacZ, and pIE4-p35.
Flow cytometric analysis. Cell cycle analysis using FACS CellQuest
(Becton Dickinson, http://www.bd.com) of ethanol-ﬁxed, propidium
iodide–stained SL2 cells was performed as described [60].
Drosophila SL2 cell RNAi. All RNAi for Drosophila SL2 cells was
performed as described [52]. Double-stranded RNA was synthesized
with T7 RiboMax (Promega, http://www.promega.com). Cells were
RNAi depleted using 50 lg of dsRNA for each gene and normalized
with luciferase dsRNA for co-RNAi treatments. For RNAi-trans-
fection experiments, 15 lg of dsRNA was included in each trans-
fection after the initial RNAi depletion. Depletion of RBF1 was
conﬁrmed by Western analysis (unpublished data). Depletion of
Aac11 RNA was conﬁrmed on microarray analysis (unpublished data).
Western analysis, antibodies, and immunocytochemistry. Western
blot and immunohistochemical analysis was performed using stand-
ard techniques. Antibodies used in this study include those against
cleaved caspase-3 (9661; Cell Signaling, http://www.cellsignal.com),
PARP (Ab2; EMD Biosciences, http://www.emdbiosciences.com), E2F1
(SC193; Santa Cruz Biotechnology, http://www.scbt.com), HA (Clone-
11; Covance, http://www.covance.com), FLAG (M2; Sigma, http://
www.signaaldrich.com), cyclin E (SC247; Santa Cruz Biotechnology),
and p14
ARF (Ab2; NeoMarkers, Lab Vision Corporation, http://www.
labvision.com). The Api5 polyclonal antibody was created by
subcloning full-length human API5 cDNA into pGEX, and GST-
Api5 fusion protein was prepared and used to inject two rabbits for
polyclonal production (Genemed Synthesis, http://www.genemedsyn.
com). Two bleeds were screened against transfected tagged and
untagged full-length Api5 to verify antigenicity. Positive bleeds were
afﬁnity-puriﬁed against PVDF membrane–bound GST-Api5, eluted
with 100 mM glycine (pH 2.5), and Centricon-puriﬁed. Speciﬁcity of
the pAB3162 afﬁnity-puriﬁed antibody was conﬁrmed using both
transfected and endogenous Api5 with and without shRNA depletion
of the speciﬁc bands.
Creation of inducible E2F1 and stable Api5–expressing Saos-2 cells.
The Tet-inducible Saos-2 cell line was created by transfecting
pCDNA6-TR (Invitrogen) into Saos-2 and selecting blasticidin (2.5
lg/ml)-resistant clones to create Saos-2-TR. The E2F1 cDNA was
cloned into pCDNA4-TO (Invitrogen) and transfected into Saos-2-TR,
and blasticidin (2.5 lg/ml)- plus zeocin (100 lg/ml)-resistant clones
were isolated and tested for induciblity with 0.1 lg/ml tetracycline.
Saos2-TR-E2F1 was transformed with retrovirus containing either
pLPC (a gift from Scott Lowe) or pLPC containing HA-tagged API5
cDNA (cloned from human cDNA library) and selected with 1 lg/ml
puromycin to create cells stably expressing Api5.
shRNA construction and lentiviral infection. A series of API5
targeting shRNAs were created in pBS-U6 as described [61]. Targeting
sequences were as follows: API5-AB 59-GGCCAGCATAAAGATGCC-
TAT-39; API5-CD 59-GGGTTGTTCAGCCAAATACTT-39; API5-EF 59-
GGCCGACCTAGAACAGACCTT-39. Sequences were subcloned from
pBS-U6 into Lentiviral vector LLP, and high-titer lentivirus was
produced as previously described [62].
Supporting Information
Figure S1. Genetic Characterization of a Recombinant Act88F-
Gal4,UAS-ced3 Transgenic Stock
Various alleles were analyzed for modiﬁcation of the ced3-dependent
phenotype in trans. Coexpression of p35 (C), but not Rbf (D) or
dominant-negative dDp (E), completely suppressed the ced3 caspase
wing phenotype. (F) The l(2)06710 Aac11 mutant does not modify the
ced3-dependent phenotype.
Found at doi:10.1371/journal.pgen.0020196.sg001 (1.2 MB PDF).
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